Ikarian Capital, LLC Syndax Pharmaceuticals Inc Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $58,080 - $87,080	4,000 New	4,000 $58,000
Q2 2021 Aug 16, 2021	SELL	$13.42 - $25.18 $549,052 - $1.03 Million	-40,913 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $1.93 Million - $2.46 Million	-100,000 Reduced 70.97%	40,913 $914,000
Q4 2020 Feb 12, 2021	BUY	$15.1 - $26.44 $2.13 Million - $3.73 Million	140,913 New	140,913 $3.13 Million
Q3 2020 Nov 16, 2020	SELL	$13.39 - $17.48 $214,240 - $279,680	-16,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $143,040 - $335,680	16,000 New	16,000 $237,000

227

88.3M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $910M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.